News
Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma in Ongoing Multicenter Study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
June 2, 2025
Read More
Obsidian Therapeutics to Present Preclinical Data Supporting Novel Application of cytoDRiVE® Platform at the American Society of Gene and Cell Therapy Annual Meeting
April 28, 2025
Read More
Obsidian Therapeutics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
April 25, 2025
Read More
ABOUT US
We are pioneers in cell and gene therapy
Leading the next generation of engineered therapeutics
Our Platform
Our proprietary
cytoDRiVE platform
Leverages drug responsive domains (DRDs) to control protein function using an FDA-approved small molecule
OBSIDIAN CAREERS
Join Our Team
Join our collaborative team of innovators who are motivated by a sense of urgency to help patients in need.
Our collective knowledge, capabilities, intellect and energy is our greatest strength.